Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $5.52 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.